BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Datamonitor Report: $156 Million Licensing Deal to Broaden Fidaxomicin's Reach


2/9/2011 9:45:11 AM

February 9, 2011 -- Japan-based Astellas Pharma has purchased the marketing rights to Optimer Pharmaceuticals' new antibiotic fidaxomicin in Europe and certain other countries.* Richard Phelps, healthcare analyst at Datamonitor, provides expert comment:

“Fidaxomicin is in development for Clostridium difficile infection (CDI), and in Phase III trials, it was shown to be statistically superior in reducing rates of disease recurrence compared to the current standard-of-care, vancomycin. It is estimated that more than 700,000 cases of CDI occur each year in the US alone, mainly affecting hospitals and long-term care facilities.

“The Astellas deal will enable Optimer to benefit from Astellas's strong capabilities in the anti-infective arena and its established relationships with payers and hospitals in Europe and other territories.

“Datamonitor believes that, combined with the highly promising Phase III data, which show clear benefits over vancomycin, the broadened geographic reach and enhanced sales and marketing capabilities resulting from the deal should notably enhance the commercial prospects for fidaxomicin and reduce the drug's dependence on the US market for sales revenue.

“Datamonitor currently forecasts sales of fidaxomicin to reach $265m across the seven major markets (the US, Japan, France, Germany, Spain, and the UK) in 2019.”

*Under the terms of the deal, Optimer will receive an upfront payment of $68m and is also eligible to receive further milestone payments totaling approximately $156m, as well as tiered double-digit royalties on sales of the drug upon regulatory approval. Astellas will be responsible for all costs associated with the development, manufacturing, and marketing of fidaxomicin in the territories covered by the deal.

Richard Phelps is available for comment. To arrange an interview or for further details regarding this release please contact Joe Dixonin the Datamonitor press office on + 44 (0)161 238 4083, or email jdixon@datamonitor.com

ABOUT DATAMONITOR

The Datamonitor Group (www.datamonitor.com) is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Sourcing, Technology and Telecoms industries. Combining our industry knowledge and experience, we assist more than 6,000 of the world’s leading companies in making better strategic and operational decisions.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES